ABSTRACT
Abstract Objective: Transcatheter aortic valve replacement has been an alternative to invasive treatment for symptomatic severe aortic stenosis in high risk patients. The primary endpoint was 30-day and 1-year mortality from any cause. Secondary endpoints were to compare the clinical and echocardiographic variation pre-and post- transcatheter aortic valve replacement, and the occurrence of complications throughout a 4-year follow-up period. Methods: This prospective cohort, nestled to a multicenter study (Registro Brasileiro de Implante de Bioprótese por Cateter), describes the experience of a public tertiary center in transcatheter aortic valve replacement. All patients who underwent this procedure between October 2011 and February 2016 were included. Results: Fifty-eight patients underwent transcatheter aortic valve replacement. The 30-day all-cause mortality was 5.2% (n=3) and after 1 year was 17.2% (n=10). A significant improvement in New York Heart Association functional classification was observed when comparing pre-and post- transcatheter aortic valve replacement (III or IV 84.4% versus 5.8%; P<0.001). A decline in peak was observed (P<0.001) and mean (P<0.001) systolic transaortic gradient. The results of peak and mean post-implant transaortic gradient were sustained after one year (P=0.29 and P=0.36, respectively). Left ventricular ejection fraction did not change significantly during follow-up (P=0.41). The most frequent complications were bleeding (28.9%), the need for permanent pacemaker (27.6%) and acute renal injury (20.6%). Conclusion: Mortality and complications in this study were consistent with worldwide experience. Transcatheter aortic valve replacement had positive clinical and hemodynamic results, when comparing pre-and post-procedure, and the hemodynamic profile of the prosthesis was sustained throughout follow-up.
Subject(s)
Humans , Male , Female , Aged , Aged, 80 and over , Aortic Valve Stenosis/surgery , Transcatheter Aortic Valve Replacement/methods , Severity of Illness Index , Brazil , Heart Valve Prosthesis/adverse effects , Echocardiography , Prospective Studies , Risk Factors , Treatment Outcome , Transcatheter Aortic Valve Replacement/adverse effectsABSTRACT
Fundamentos: Estudos demonstram a importante prevalência do déficit de vitamina D (vit. D) em pacientes com insuficiência cardíaca com fração deejeção reduzida (ICFER). O déficit de vit. D se relaciona com a piora na qualidade de vida e redução do desempenho funcional. Com o envelhecimento, a insuficiência cardíaca com fração de ejeção normal (ICFEN) tornar-se-á o tipo de insuficiência cardíaca mais comum, com resultados referentes ao prognóstico semelhantes aos da ICFER. Apesar das evidências daação benéfica da vit. D no sistema cardiovascular em pacientes com ICFER, não há estudos clínicos que demonstrem a melhora morfofuncional cardiovascularcom a suplementação de vit.D em pacientes com ICFEN. Objetivo: Demonstrar a melhora da qualidade de vida e função diastólica em pacientes com ICFEN, após suplementação de vit. D. Métodos: E s t u d o p ro s p e c t i v o , d u p l o-c e g o randomizado, placebo controlado, envolvendo 40 pacientes com ICFEN e deficiência de vit. D (25OHD<30ng/mL), por 20 semanas de tratamento. Os pacientes receberão suplementação de 100.000UI decolecalciferol ou placebo no início do estudo e na 10ª semana, sob supervisão médica. Os pacientes serão avaliados por: testes funcionais (timed up and go test e 6 minute walk test), exames laboratoriais, questionário Minnesota Living with Heart Failure, eletrocardiograma e ecoDopplercardiograma, avaliando a função sistólica, a diastólica e o remodelamento ventricular no início doestudo, em 10 semanas e em 20 semanas. Conclusão: O estudo FITNESS avaliará o impacto morfofuncional cardiovascular e na qualidade de vida em 20 semanas na suplementação de colecalciferol em pacientes com ICFEN e déficit de vit. D.
Background: Studies have shown a significant prevalence of vitamin D (Vit. D) deficits in heart failure patients with reduced ejection fraction(HFREF), related to poorer quality of life andreductions in functional performance. With anaging population, heart failure with preserved ejection fraction (HFPEF) will become the most common type of heart failure (HF), with similar results for HFREF predictions. Despite evidence of the beneficial action of vit. D on the cardiovascular system in HFREF patients, there are no clinical s t u d i e s demo n s t r a t i n g c a rd i o v a s c u l a r morphofunctional improvement through vit.D supplementation in HFPEF patients. Objective: To demonstrate improvements in the quality of life and diastolic function for FPEF patients taking vit. D supplements. Methods: Prospective, double-blind, randomized, placebo-controlled study, with 40 patients with HFNEF and vit. D deficiency (25OHD <30ng/mL)for 20 weeks of treatment. Patients will receive supplements of 100,000IU of cholecalciferol (Vit. D3)or placebo at baseline and at 10 weeks under medical supervision. They will be assessed by: functional tests (timed up-and-go test and 6-minute walk test),laboratory examinations, the Minnesota Living with Heart Failure Questionnaire, electrocardiogram, evaluating systolic and diastolic functions and ventricular remodeling at baseline, and at 10 and 20weeks.Conclusion: The FITNESS study will evaluate cardiovascular morphofunctional impacts and effects on the quality of life during 20 weeks of cholecalciferol supplementation in HFPEF patients with vit. D deficits.